Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 1/20 | 0.47 |
| ▸ | SSTR1 | P30872 | 3/20 | 0.42 |
| ▸ | SSTR2 | P30874 | 3/20 | 0.42 |
| ▸ | SSTR4 | P31391 | 3/20 | 0.42 |
| ▸ | SSTR3 | P32745 | 3/20 | 0.42 |
| ▸ | SSTR5 | P35346 | 3/20 | 0.42 |
| ▸ | PTPN1 | P18031 | 5/20 | 0.42 |
| ▸ | CDC25B | P30305 | 5/20 | 0.42 |
| ▸ | TACR2 | P21452 | 1/20 | 0.41 |
| ▸ | BCHE | P06276 | 1/20 | 0.40 |
| ▸ | PTPN2 | P17706 | 2/20 | 0.40 |
| ▸ | PTPN6 | P29350 | 2/20 | 0.40 |
| ▸ | PTPN11 | Q06124 | 2/20 | 0.40 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.40 |
| ▸ | MTOR | P42345 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL181126 | 1.00 | SLC6A2 (0.47) | SLC6A2SSTR1SSTR2SSTR4SSTR3 | |
| SCHEMBL181077 | 1.00 | SLC6A2 (0.47) | SLC6A2SSTR1SSTR2SSTR4SSTR3 | |
| SCHEMBL16581477 | 1.00 | SLC6A2 (0.47) | SLC6A2SSTR1SSTR2SSTR4SSTR3 | |
| SCHEMBL6929599 | 1.00 | SLC6A2 (0.47) | SLC6A2SSTR1SSTR2SSTR4SSTR3 | |
| SCHEMBL2172329 | 1.00 | SLC6A2 (0.47) | SLC6A2SSTR1SSTR2SSTR4SSTR3 | |
| SCHEMBL9853879 | 0.96 | SLC6A2 (0.47) | SLC6A2SSTR1SSTR2SSTR4SSTR3 | |
| SCHEMBL9853878 | 0.96 | SLC6A2 (0.47) | SLC6A2SSTR1SSTR2SSTR4SSTR3 | |
| SCHEMBL1776774 | 0.95 | SLC6A2 (0.47) | SLC6A2SSTR1SSTR2SSTR4SSTR3 | |
| SCHEMBL13224920 | 0.90 | SLC6A2 (0.56) | SLC6A2BCHE | |
| SCHEMBL2536430 | 0.90 | SLC6A2 (0.56) | SLC6A2BCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2334687-B9 | DIOXA-BICYCLO[3.2.1.]OCTANE-2,3,4-TRIOL DERIVATIVES | PFIZER (US) | 2012-08-08 | — | — | EP | disclosed |
| EP-2334687-B1 | DIOXA-BICYCLO[3.2.1.]OCTANE-2,3,4-TRIOL DERIVATIVES | PFIZER (US) | 2012-01-04 | — | — | EP | disclosed |
| US-7989602-B2 | having biological activity similar to PIM (acyl glycerol phosphatidylinositol manno-oligosacccharide) activity; asthma, allergic rhinitis, dermatitis, psoriasis, inflammatory bowel disease including Crohn's disease and ulcerative colitis, rheumatoid arthritis, multiple sclerosis, diabetes, systemic lupus | THE MALAGHAN INSTITUTE OF MEDICAL RESEARCH (NZ) | 2011-08-02 | — | — | US | disclosed |
| US-20100202971-A1 | COMPOUND HAVING TUMOR-RESIDENT PROPERTY | OHTA KEISUKE | 2010-08-12 | — | — | US | disclosed |
| US-20080249037-A1 | Synthetic Molecules Having Immune Activity | UNIVERSITY OF OTAGO (NZ) | 2008-10-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100202971-A1 | COMPOUND HAVING TUMOR-RESIDENT PROPERTY | HRH3, HRH4, HNRNPH3 | SLC6A2 2975/4885SSTR1 417/4885SSTR2 529/4885 |
| US-20080249037-A1 | Synthetic Molecules Having Immune Activity | ALG1, PAG1, SIGLEC7 | SLC6A2 4876/4885SSTR1 4558/4885SSTR2 4332/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.